BrainStorm Q3 2026: $1.7M Quarterly Loss, Only $0.35M Cash Against $13.2M Current Liabilities
BCLI has more than doubled off its 52-week low of $0.459 on light trading volume (0.3× avg).
Summary
BrainStorm posted a $1.7 million net loss for Q3 2026 and ended the quarter with about $0.35 million of cash against $13.2 million of current liabilities, leaving the ALS-focused biotech dependent on new financing to fund its planned Phase 3b trial.
Key Events · Earnings and Guidance · BCLI
-
Q3 2026 Net Loss Narrows to $1.7M
For the quarter ended September 30, 2026, the net loss was approximately $1.7 million, or $(0.14) per share, compared with a $2.1 million loss, or $(0.19) per share, in Q3 2025. R&D spending fell to $0.5 million from $0.9 million, and G&A to $1.09 million from $1.15 million.
-
Cash of $0.35M Against $13.2M Current Liabilities
Cash, cash equivalents and restricted cash totaled approximately $0.35 million at September 30, 2026, while total current liabilities reached $13.2 million, including $7.5 million of accounts payable and $3.3 million of employee-related liabilities. Total stockholders' deficit stood at $12.3 million.
-
Short-Term Loans Nearly Double
Short-term loans climbed to $1.9 million at September 30, 2026 from $1.0 million at December 31, 2025, widening the funding gap alongside a $0.44 million nine-month net financial expense.
-
Phase 3b ENDURANCE Still Pre-Launch
BrainStorm says it continues preparations to initiate the Phase 3b ENDURANCE study of NurOwn in earlier-stage ALS under an FDA-agreed Special Protocol Assessment. The trial has not yet begun, and no start date or funding source is stated.
Analysis · BCLI · Life Sciences
The balance sheet, not the headline loss, is the story here. As of September 30, 2026, BrainStorm held roughly $0.35 million in cash and restricted cash against $13.2 million of current liabilities, including $7.5 million of accounts payable and $3.3 million owed to employees. No near-term operating plan closes a working-capital hole of that size, and it compounds the going-concern warning and material weakness already disclosed in the Q2 2026 10-Q. The company's entire future rests on the Phase 3b ENDURANCE trial in ALS, which has an FDA-agreed Special Protocol Assessment but has not yet started, and on raising money it does not currently have. Any financing from this position would likely be heavily dilutive to the 14.26 million shares outstanding, already up from 11.03 million at year-end 2025.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BCLI was trading at $0.95 on OTC in the Life Sciences sector, with a market capitalization of approximately $10.5M. The 52-week trading range was $0.46 to $1.69. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.